Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Buy
53
AKRO Quote, Financials, Valuation and Earnings
Last price:
$44.85
Seasonality move
:
13.12%
Day range:
$44.08 - $46.47
52-week range:
$17.86 - $58.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.76x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
127.65%
Market cap:
$3.6B
Revenue:
--
EPS (TTM):
-$3.75
Analysts' Opinion
-
Consensus RatingAkero Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $77.64, Akero Therapeutics has an estimated upside of 73.03% from its current price of $44.87.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $60.00 representing 100% downside risk from its current price of $44.87.
Fair Value
-
According to the consensus of 9 analysts, Akero Therapeutics has 73.03% upside to fair value with a price target of $77.64 per share.
AKRO vs. S&P 500
-
Over the past 5 trading days, Akero Therapeutics has overperformed the S&P 500 by 6.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Akero Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Akero Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Akero Therapeutics reported revenues of --.
Earnings Growth
-
Akero Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Akero Therapeutics reported earnings per share of -$0.99.
Enterprise value:
2.9B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-12.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$115.2M | -$172.9M | -$285.4M | -$61.9M | -$78M | |
| EBITDA | -$111.3M | -$148.6M | -$247.4M | -$54.3M | -$68.8M | |
| Diluted EPS | -$2.92 | -$2.88 | -$3.75 | -$1.02 | -$0.99 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $271.3M | $193.6M | $355.2M | $560M | $770.4M | |
| Total Assets | $273.3M | $195.5M | $356.6M | $580.3M | $825.9M | |
| Current Liabilities | $13.1M | $25.1M | $19.1M | $19.1M | $39.8M | |
| Total Liabilities | $14.6M | $26.4M | $30M | $45M | $75.8M | |
| Total Equity | $258.7M | $169.1M | $326.6M | $535.3M | $750.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.5M | -$145.4M | -$230.1M | -$48.6M | -$67.1M | |
| Cash From Investing | -$63.8M | -$223.6M | -$109.7M | $12.8M | $15.3M | |
| Cash From Financing | $255.6M | $353.3M | $445.8M | $502K | $76M | |
| Free Cash Flow | -$92.5M | -$145.4M | -$231.1M | -$48.6M | -$67.1M | |
AKRO
Sector
Market Cap
$3.6B
$35.8M
Price % of 52-Week High
76.83%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
127.65%
-38.89%
Beta (5-Year)
-0.123
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$42.83
200-day SMA
Buy
Level
$33.75
Bollinger Bands (100)
Buy
Level
29.5 - 48.8
Chaikin Money Flow
Buy
Level
46.4M
20-day SMA
Buy
Level
$39.21
Relative Strength Index (RSI14)
Buy
Level
62.23
ADX Line
Buy
Level
22.28
Williams %R
Sell
Level
-15.0801
50-day SMA
Buy
Level
$42.66
MACD (12, 26)
Buy
Level
0.82
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
46.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Stock Forecast FAQ
In the current month, AKRO has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AKRO average analyst price target in the past 3 months is $77.64.
-
Where Will Akero Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Akero Therapeutics share price will rise to $77.64 per share over the next 12 months.
-
What Do Analysts Say About Akero Therapeutics?
Analysts are divided on their view about Akero Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Akero Therapeutics is a Sell and believe this share price will drop from its current level to $60.00.
-
What Is Akero Therapeutics's Price Target?
The price target for Akero Therapeutics over the next 1-year time period is forecast to be $77.64 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AKRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Akero Therapeutics is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AKRO?
You can purchase shares of Akero Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Akero Therapeutics shares.
-
What Is The Akero Therapeutics Share Price Today?
Akero Therapeutics was last trading at $44.85 per share. This represents the most recent stock quote for Akero Therapeutics. Yesterday, Akero Therapeutics closed at $44.87 per share.
-
How To Buy Akero Therapeutics Stock Online?
In order to purchase Akero Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
